Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Verrica Pharmaceuticals (VRCA) Change in Acquisitions & Divestments (2021 - 2022)

Verrica Pharmaceuticals (VRCA) has 2 years of Change in Acquisitions & Divestments data on record, last reported at $7.0 million in Q4 2022.

  • For Q4 2022, Change in Acquisitions & Divestments fell 50.7% year-over-year to $7.0 million; the TTM value through Sep 2023 reached $7.0 million, down 89.43%, while the annual FY2022 figure was $59.0 million, 14.48% down from the prior year.
  • Change in Acquisitions & Divestments reached $7.0 million in Q4 2022 per VRCA's latest filing, up from $2.0 million in the prior quarter.
  • Across five years, Change in Acquisitions & Divestments topped out at $47.5 million in Q1 2022 and bottomed at $2.0 million in Q3 2022.